
    
The genomic variant c.716A>T p.Asn239Ile, denoted as rs1057519999, is a missense mutation located in the TP53 gene. TP53, commonly known as the tumor suppressor p53, plays a critical role in cellular stress responses, including DNA repair, cell cycle arrest, apoptosis, senescence, and metabolism. Mutations in this gene are associated with a variety of human cancers due to its pivotal function in maintaining genomic stability and preventing oncogenesis.The specific variant p.Asn239Ile has been studied in the context of its impact on the TP53 protein function. The asparagine at position 239 is situated within the DNA binding domain of p53, a region that is highly conserved across species, indicating its importance in the protein's function [1]. This particular residue, N239, has been identified as a medium hotspot for mutations, which suggests that alterations at this site could have significant implications for the protein's ability to interact with DNA and regulate gene expression [1].Functional assays have demonstrated that the p.Asn239Ile variant results in a loss of function of the TP53 protein. Specifically, the mutant form of p53 with the N239I substitution has been shown to lose its DNA binding ability to promoters regulated by wild-type p53. This loss of function extends to the regulation of transcription of key genes involved in cell cycle arrest and apoptosis, such as p21 Cip1/Waf1, cyclin G, PUMA, and Bax, particularly in response to DNA damage signals like irradiation [1]. Consequently, the p.Asn239Ile variant impairs the tumor suppressive capabilities of the TP53 protein, which could potentially contribute to tumorigenesis.Despite the loss of function, the gain-of-function effects of the p.Asn239Ile variant have not been fully elucidated. However, it has been suggested that different p53 mutants, including those at the N239 residue, can vary dramatically in their oncogenic potential and interactions with other oncogenes, such as Ras [1]. This highlights the complexity of TP53 mutations and the need for further research to understand the full spectrum of their biological consequences.In summary, the c.716A>T p.Asn239Ile rs1057519999 variant in the TP53 gene is a pathogenic missense mutation that compromises the DNA binding and transcriptional regulatory functions of the p53 protein. This mutation is associated with a loss of tumor suppressor activity, which is critical for the prevention of cancer development. The variant's prevalence in ClinVar, with a majority of submissions classifying it as pathogenic, further supports its significance in disease pathology.

ゲノム変異 c.716A>T p.Asn239Ile（rs1057519999）は、TP53遺伝子に位置するミスセンス変異です。TP53は一般的に腫瘍抑制因子p53として知られており、DNA修復、細胞周期停止、アポトーシス、老化、代謝など、細胞ストレス応答において重要な役割を果たします。この遺伝子の変異は、ゲノムの安定性を維持し、発がんを防ぐという重要な機能のために、さまざまな人間のがんと関連しています。特定の変異であるp.Asn239Ileは、TP53タンパク質の機能への影響に関して研究されています。239番目の位置にあるアスパラギン（Asn）は、p53のDNA結合ドメイン内に位置しており、この領域は種を超えて高度に保存されているため、タンパク質の機能において重要であることが示されています[1]。この特定の残基であるN239は、変異の中程度のホットスポットとして特定されており、この部位での変化がDNAとの相互作用や遺伝子発現の調節能力に重大な影響を与える可能性があることを示唆しています[1]。

機能アッセイでは、p.Asn239Ile変異がTP53タンパク質の機能喪失を引き起こすことが示されています。具体的には、N239I置換を持つ変異型p53は、野生型p53によって調節されるプロモーターへのDNA結合能力を失うことが示されています。この機能喪失は、DNA損傷信号（例えば放射線照射）に応答して、細胞周期停止やアポトーシスに関与する重要な遺伝子（p21 Cip1/Waf1、サイクリンG、PUMA、Baxなど）の転写調節にも及びます[1]。その結果、p.Asn239Ile変異はTP53タンパク質の腫瘍抑制能力を損ない、発がんに寄与する可能性があります。

機能喪失にもかかわらず、p.Asn239Ile変異の機能獲得効果は完全には解明されていません。しかし、N239残基を含むさまざまなp53変異体が、発がん性の潜在能力やRasなどの他のオンコジェンとの相互作用において劇的に異なる可能性があることが示唆されています[1]。これは、TP53変異の複雑さを浮き彫りにし、それらの生物学的影響の全範囲を理解するためのさらなる研究の必要性を強調しています。

まとめると、TP53遺伝子のc.716A>T p.Asn239Ile rs1057519999変異は、p53タンパク質のDNA結合および転写調節機能を損なう病原性ミスセンス変異です。この変異は腫瘍抑制活性の喪失と関連しており、がんの発症を防ぐために重要です。この変異のClinVarにおける頻度は高く、大多数の提出が病原性として分類されていることから、疾患病理学におけるその重要性がさらに支持されています。
    
## References
- [1] Jia S et al. (2012). "The gain of function of p53 mutant p53S in promoting tumorigenesis by cross-talking with H-RasV12." International journal of biological sciences, 8(5) [PubMed](https://pubmed.ncbi.nlm.nih.gov/22553460/)
- [2] Mendoza RP et al. (2024). "Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization." Cancer medicine, 13(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38164123/)
- [3] Winther-Larsen A et al. (2017). "Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients." British journal of cancer, 117(5) [PubMed](https://pubmed.ncbi.nlm.nih.gov/28683468/)
- [4] Demir O et al. (2011). "Ensemble-based computational approach discriminates functional activity of p53 cancer and rescue mutants." PLoS computational biology, 7(10) [PubMed](https://pubmed.ncbi.nlm.nih.gov/22028641/)
- [5] Tan YH et al. (2010). "CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases." PloS one, 5(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/20126411/)
- [6] Liu S et al. (2017). "A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer." eLife, 6() [PubMed](https://pubmed.ncbi.nlm.nih.gov/28826481/)
- [7] Han Z et al. (1999). "Dominant-negative p53 mutations in rheumatoid arthritis." Arthritis and rheumatism, 42(6) [PubMed](https://pubmed.ncbi.nlm.nih.gov/10366100/)
- [8] Nian Y et al. (2013). "Triterpenes from the aerial parts of Cimicifuga yunnanensis and their antiproliferative effects on p53(N236S) mouse embryonic fibroblasts." Journal of natural products, 76(5) [PubMed](https://pubmed.ncbi.nlm.nih.gov/23621813/)
- [9] Bashashati A et al. (2013). "Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling." The Journal of pathology, 231(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/23780408/)
- [10] Lin R et al. (2021). "Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review." Frontiers in oncology, 11() [PubMed](https://pubmed.ncbi.nlm.nih.gov/34540698/)
- [11] Chen Y et al. (2024). "Aggresome formation promotes ASK1/JNK signaling activation and stemness maintenance in ovarian cancer." Nature communications, 15(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38351029/)
- [12] Khalil SS et al. (2024). "Mutations in the TP53, VEGFA, and CTH Genes as Key Molecular Markers for the Diagnosis of Glioblastoma." Cureus, 16(5) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38933650/)
- [13] Zheng J et al. (2010). "Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment." Cell cycle (Georgetown, Tex.), 9(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/20016289/)
- [14] Gallant JN et al. (2019). "Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibition." NPJ precision oncology, 3() [PubMed](https://pubmed.ncbi.nlm.nih.gov/30793038/)
- [15] Diefenbach RJ et al. (2020). "Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA." Cancers, 12(8) [PubMed](https://pubmed.ncbi.nlm.nih.gov/32785074/)

    
## ClinVar Submissions
- **[RCV002374626](https://www.ncbi.nlm.nih.gov/clinvar/RCV002374626/)**: Hereditary cancer-predisposing syndrome
- **[RCV000567507](https://www.ncbi.nlm.nih.gov/clinvar/RCV000567507/)**: Hereditary cancer-predisposing syndrome
- **[RCV002289529](https://www.ncbi.nlm.nih.gov/clinvar/RCV002289529/)**: Li-Fraumeni syndrome 1
- **[RCV001851021](https://www.ncbi.nlm.nih.gov/clinvar/RCV001851021/)**: Li-Fraumeni syndrome
- **[RCV002510885](https://www.ncbi.nlm.nih.gov/clinvar/RCV002510885/)**: not provided
- **[RCV000417510](https://www.ncbi.nlm.nih.gov/clinvar/RCV000417510/)**: Neoplasm of the large intestine
- **[RCV000418162](https://www.ncbi.nlm.nih.gov/clinvar/RCV000418162/)**: Lung adenocarcinoma
- **[RCV000418854](https://www.ncbi.nlm.nih.gov/clinvar/RCV000418854/)**: Neoplasm of the large intestine
- **[RCV000420011](https://www.ncbi.nlm.nih.gov/clinvar/RCV000420011/)**: Papillary renal cell carcinoma type 1
- **[RCV000420547](https://www.ncbi.nlm.nih.gov/clinvar/RCV000420547/)**: Papillary renal cell carcinoma type 1
- **[RCV000424579](https://www.ncbi.nlm.nih.gov/clinvar/RCV000424579/)**: Squamous cell carcinoma of the head and neck
- **[RCV000425771](https://www.ncbi.nlm.nih.gov/clinvar/RCV000425771/)**: Uterine carcinosarcoma
- **[RCV000426368](https://www.ncbi.nlm.nih.gov/clinvar/RCV000426368/)**: Malignant neoplasm of body of uterus
- **[RCV000427640](https://www.ncbi.nlm.nih.gov/clinvar/RCV000427640/)**: Lung adenocarcinoma
- **[RCV000428926](https://www.ncbi.nlm.nih.gov/clinvar/RCV000428926/)**: Breast neoplasm

    